Pulse Biosciences, Inc.

NasdaqCM:PLSE Stock Report

Market Cap: US$3.8b

Pulse Biosciences Management

Management criteria checks 2/4

Pulse Biosciences' CEO is Paul LaViolette, appointed in Jan 2025, has a tenure of 1.67 years. total yearly compensation is $14.20M, comprised of 5% salary and 95% bonuses, including company stock and options. directly owns 0.022% of the company’s shares, worth $853.73K. The average tenure of the management team and the board of directors is 2.9 years and 8.8 years respectively.

Key information

Paul LaViolette

Chief executive officer

US$14.2m

Total compensation

CEO salary percentage4.99%
CEO tenure1.7yrs
CEO ownership0.02%
Management average tenure2.9yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

Narrative Update • Sep 09

PLSE: Pivotal nsPFA Trials And Early Data Will Drive Bullish Outlook

Analysts have revised their fair value estimate for Pulse Biosciences to $58 from $35, citing growing confidence in the company's differentiated nanosecond pulse field ablation platform, positive early clinical signals, and the potential impact of ongoing pivotal studies and future partnerships. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences has taken a more constructive tone, with several bullish analysts highlighting the company’s nanosecond pulsed field ablation platform and early clinical data as key supports for their valuation work.
Narrative Update • Aug 26

PLSE: Pivotal Nanosecond Ablation Data And Partnerships Will Shape 3b Market Access

Analysts have lifted the fair value estimate for Pulse Biosciences to $45.25 from $41, citing Street research that highlights its differentiated nanosecond pulsed field ablation platform, positive early clinical data, progress in pivotal studies, and what they view as improving success probabilities following recent updates. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform, the pace of clinical development, and how these factors feed into valuation and execution risk for investors following the story into late 2026.
Narrative Update • Aug 12

PLSE: Clinical And Regulatory Progress Will Test Access To 3b Ablation Market

The analyst price target for Pulse Biosciences has been reset from about $30.67 to $41.00, with analysts pointing to improving success probabilities for its nanosecond pulsed field ablation platform and continued clinical and regulatory progress as key drivers of their updated views. Analyst Commentary Recent Street research on Pulse Biosciences highlights both optimism around the nanosecond pulsed field ablation platform and a focus on the execution risks that come with an early stage commercial story.
New Narrative • Aug 07

Slower Pulsed Field Ablation Adoption Will Limit Revenue Scale And Delay Profitability

Catalysts About Pulse Biosciences Pulse Biosciences develops medical devices based on nanosecond pulsed field ablation technology for cardiac and thyroid procedures. What are the underlying business or industry changes driving this perspective?
Narrative Update • Jul 29

PLSE: Cardiac Ablation Data And Index Inclusion Will Guide Fairly Valued Outlook

Analysts have lifted their price target on Pulse Biosciences to $35 from $30, citing preliminary support for the nsPFA platform's safety and efficacy profile in cardiac ablation and its potential to address a large electrophysiology market opportunity. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences points to growing confidence in the potential of its nanosecond pulsed field ablation, or nsPFA, platform in cardiac ablation.
Narrative Update • Jul 10

PLSE: Ablation Platform And Clinical Data Will Drive Access To 3b Market

Analysts have lifted the fair value estimate for Pulse Biosciences from about $22 to roughly $30.67 per share, citing the company’s differentiated nanosecond pulsed field ablation platform and the roughly $3 billion electrophysiologists ablation market opportunity as key drivers behind a Street price target of $32. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform and how that might justify the latest fair value estimate and price targets around US$32 per share.
Narrative Update • Jun 26

PLSE: Nanosecond Cardiac Ablation Platform Will Pursue Expanding Electrophysiology Opportunity

Analysts raised their price target on Pulse Biosciences stock from $30 to $32, citing its differentiated nanosecond pulsed field cardiac ablation platform and the $3 billion electrophysiology ablation market, which they estimate is growing 10% to 15% annually, with potential for the company to capture a meaningful share. Analyst Commentary Bullish analysts covering Pulse Biosciences emphasize that the stock is now being valued around a clearly defined opportunity in cardiac ablation, supported by a specific US$32 price target.
New Narrative • Feb 09

Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform

Catalysts About Pulse Biosciences Pulse Biosciences develops and commercializes medical devices that use proprietary nanosecond pulse field ablation technology for soft tissue and cardiac applications. What are the underlying business or industry changes driving this perspective?
Analysis Article • Dec 21

Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 12

Here's Why We're Not At All Concerned With Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Feb 07

We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Pulse...
Seeking Alpha • May 16

Pulse Biosciences Stock: Signs Of Life Following Q1 Update

Summary We recap Q1 developments from Pulse Biosciences, Inc. The FDA has cleared the company's percutaneous electrode system, while the surgical clamp device for cardiac indications is still in the preclinical trial phase. Pulse Biosciences is making progress in its commercialization strategy, but financial uncertainties may keep the stock under pressure. Read the full article on Seeking Alpha
Analysis Article • May 10

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 25

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Pulse Biosciences...
Analysis Article • Sep 04

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Paul LaViolette's remuneration changed compared to Pulse Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$80m

Mar 31 2026n/an/a

-US$75m

Dec 31 2025US$14mUS$709k

-US$73m

Sep 30 2025n/an/a

-US$75m

Jun 30 2025n/an/a

-US$68m

Mar 31 2025n/an/a

-US$60m

Dec 31 2024US$3mn/a

-US$54m

Compensation vs Market: Paul's total compensation ($USD14.20M) is above average for companies of similar size in the US market ($USD7.02M).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.

CEO

Paul LaViolette (68 yo)

1.7yrs
Tenure
US$14,200,988
Compensation

Mr. Paul Arthur LaViolette, M.B.A. is Member of Advisory Board of Carvolix SA from April 2026. He is Director of Vibrato Medical, Inc. Mr. LaViolette is President, Chief Executive Officer, at Pulse Bioscie...

Leadership Team

NamePositionTenureCompensationOwnership
Paul LaViolette
President1.7yrsUS$14.20m0.022%
$ 853.7k
Jon Skinner
Chief Financial Officer1.6yrsUS$2.88m0.0022%
$ 83.8k
Darrin Uecker
CTO & Director4yrsUS$869.89k0.40%
$ 15.3m
Liane Teplitsky
Chief Operating Officerless than a yearno data0.0057%
$ 220.5k
Steven Weber
VP of Accounting1.2yrsno datano data
Kenneth B. Stratton
General Counsel & Corporate Secretary5.3yrsno datano data
Patty Perla
Vice President of Human Resources6.5yrsno datano data
David Danitz
Senior Vice President of Engineering5yrsno datano data
Gansevoort Dunnington
Chief Medical Officer3.3yrsno datano data
Niv Ad
Chief Science Officer of Cardiac Surgery2.9yrsno datano data
David Kenigsberg
Chief Medical Officer1.9yrsno datano data
2.9yrs
Average Tenure
53.5yo
Average Age

Experienced Management: PLSE's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul LaViolette
President2.1yrsUS$14.20m0.022%
$ 853.7k
Darrin Uecker
CTO & Director11yrsUS$869.89k0.40%
$ 15.3m
Richard van den Broek
Independent Director6.1yrsUS$412.74k0%
$ 0
Robert Duggan
Independent Co-Chairman8.8yrsUS$633.14k68.45%
$ 2.6b
Maria Degois-Sainz
Independent Directorless than a yearno datano data
Mahkam Zanganeh
Independent Director9.6yrsUS$704.61k1.22%
$ 47.1m
Manmeet Soni
Lead Independent Director8.8yrsUS$631.80k0%
$ 0
8.8yrs
Average Tenure
60yo
Average Age

Experienced Board: PLSE's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/21 17:40
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pulse Biosciences, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William PlovanicCanaccord Genuity
Keith HintonFreedom Capital Markets
Anthony PetroneMizuho Securities USA LLC